Australia's Cleo Diagnostics jumps after cancer screening test meets milestone
Yesterday 04:26
BUZZ-Australia's Cleo Diagnostics jumps after cancer screening test meets milestone ** Shares of Cleo Diagnostics COV.AX advance as much as 16.4% to A$0.355, their biggest intraday pct gain since March 25
** Ovarian cancer diagnostics firm says its prototype screening test met or exceeded all pre-defined performance targets in its first proof-of-concept study
** Co says test outperformed ovarian cancer biomarker CA125 in detecting both early-stage and overall cancers
** Adds, development will now advance to larger group trials to prepare for final, real-world patient testing
** Over 184,000 shares change hands, about 1.3x the 30-day average
** YTD, stock down 47.1%, including session's moves
(Reporting by Subhalakshmi Dey in Bengaluru)
Recent news on CLEO Diagnostics
See all newsAustralia's Cleo Diagnostics jumps after cancer screening test meets milestone
Brief: Cleo Diagnostics Files Patents For Its Ovarian Cancer Screening Test
Australia's Cleo Diagnostics jumps as ovarian cancer test hits validation milestone
Brief: Cleo Diagnostics Receives First Batch Of Commercially Manufactured Test Kits
Brief: Cleo Diagnostics Raises A$5M